To observe the impact of ShengxueⅡ on megalocaryocyte in bone marrow in mice with idiopathic thrombocytopenic purpura (ITP).Methods:Thirty male and female mice with thrombocytopenia were treated by Chinese medicine, or by hormone respectively for 15 days, and megalocaryocyte in bone marrow were counted.Results:Either the medicine group or hormone group had significant differences when comparing with the model group (P<0.01); but without significant differences when comparing with the normal group (P>0.05); There was no significant different between the medicine group and hormone group (P>0.05).Conclusion:ShengxueⅡcan promote megalocaryocyte differentiation and produce blood platelet, indicating it is a safer and more effective treatment than hormone for the treatment of idiopathic thrombocytopenic purpura.